Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Consensus Price Target of $103.33 According to Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned a consensus rating of “Hold” from the twenty-two analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $103.33.

Several equities analysts have recently weighed in on ZBH shares. Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Wednesday, August 5th. Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Sanford C. Bernstein increased their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th.

Insider Transactions at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider directly owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Kevin R. Thornal sold 5,691 shares of the firm’s stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. OMERS ADMINISTRATION Corp acquired a new stake in shares of Zimmer Biomet in the second quarter valued at approximately $922,000. Hsbc Holdings PLC acquired a new position in Zimmer Biomet during the second quarter worth $35,417,000. Legal & General Group Plc acquired a new position in Zimmer Biomet during the second quarter worth $126,167,000. Rakuten Investment Management Inc. purchased a new stake in Zimmer Biomet in the 2nd quarter valued at $2,945,000. Finally, Munich Reinsurance Co Stock Corp in Munich purchased a new stake in Zimmer Biomet in the 2nd quarter valued at $3,753,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of ZBH traded up $0.52 during mid-day trading on Friday, hitting $94.90. 1,935,274 shares of the company were exchanged, compared to its average volume of 2,126,925. The stock has a market cap of $18.10 billion, a price-to-earnings ratio of 23.09, a price-to-earnings-growth ratio of 1.78 and a beta of 0.49. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $106.88. The company has a 50 day moving average of $95.31 and a 200-day moving average of $91.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The company had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the previous year, the firm posted $2.07 EPS. Zimmer Biomet’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Analysts expect that Zimmer Biomet will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.

Its portfolio also includes orthopedic surgical equipment, robotic- and computer-assisted technologies, biologics and other solutions designed to support joint reconstruction, spine procedures and dental applications.